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Purpose: It is known that cyclooxygenase (COX)-2
expression is increased in Barrett’s esophagus and esophageal
adenocarcinomas. We studied COX-2 expression and the
effect sulindac has on the genesis of Barrett’s esophagus and
adenocarcinoma in rats undergoing esophagogastroduodenal
anastomosis (EGDA). Materials and Methods: Fifty-one rats
were divided into a control group (n = 27), a 500 ppm
sulindac-treated group (n = 15) and 1000 ppm sulindac-treated
group (n = 9). Randomly selected rats were killed by diethyl
ether inhalation at 20 and 40 weeks after surgery. Results: At
40 weeks, rats treated with 1000 ppm sulindac showed narrower
esophageal diameter and milder inflammation than the control
rats. At 40 weeks, the incidence of Barrett’s esophagus was
similar between control and sulindac-treated groups, but the
incidence of adenocarcinoma was significantly lower in the
1000 ppm sulindac-treated group than either the control or 500
ppm sulindac-treated groups. COX-2 was significantly
increased in the lower esophagus of control rats killed at 40
weeks. Cyclin D1 expression was negligible in the sulindac-
treated group compared with the control group. Conclusion:
We suggest that the chemopreventive effect of sulindac is
related to decreased COX-2 and cyclin D1 expression, which
may be influenced by reduced inflammation.
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INTRODUCTION
Esophageal adenocarcinomas are becoming
more common.
1,2 Barrett's esophagus (BE) is as-
sumed to result from chronic esophageal reflux
and is a precursor to esophageal adenocarcinoma.
3-6 Reflux of duodenal contents and gastric acid in
humans seems to contribute to Barrett’s esophagus.
7
The precise mechanism by which reflux contents
cause Barrett’s esophagus and predispose neoplasia
is uncertain. Several recent studies, however, have
shown that reflux constituents, including acid and
bile, can regulate cyclooxygenase-2 (COX-2) ex-
pression.
8-10 COX-2 is transiently induced by
proinflammatory cytokines and growth factors and
is involved in inflammation and mitogenesis.
11 In
addition, prostaglandin E2 (PGE2) has been shown
to induce malignant change in epithelial cells
through immunosuppression, inhibiting apoptosis,
increasing epithelial cell metastatic potential, and
promoting angiogenesis.
12-16
Non-steroidal anti-inflammatory drugs (NSAIDs)
may protect against cancers in the gastrointestinal
tract. The protective effect is particularly well
documented in the colon and rectum. For example,
a 40 - 50% reduction in colon cancer incidence was
reported among regular aspirin users.
17 Recent
studies have confirmed that regular NSAID usage
is also associated with a reduced risk of stomach
cancer and esophageal cancer.
18-22 The molecular
mechanisms underlying these chemopreventive
effects are not well understood and are the subject
of ongoing debate. One of the most widely
accepted mechanisms for the NSAID anticancer
effect concerns reduced prostaglandin synthesis
due to reduced COX activity. Recent studies have
reported that COX-2 inhibitors prevent esophageal
adenocarcinoma in rats.
23,24 Oyama et al. suggest
that celecoxib is effective in preventing Barrett’s
esophagus and adenocarcinoma by suppressing
esophagitis in rats.
23
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In this study, we studied the effect of sulindac
on Barrett’s esophagus and esophageal adeno-
carcinoma in surgically induced gastroduodenal
reflux and COX-2 expression.
MATERIALS AND METHODS
Animals and surgical procedures
Seven-week old male Sprague-Dawley rats
(Kist, Taejun, Korea) were used in this study.
Throughout the experiment, all rats were housed
in a controlled environment with a 12-h light/
dark cycle at 22 ± 2℃. After a 1-week acclimation
period, a total of 60 rats underwent operative
procedures. Solid food was withdrawn for 24 h
and water for 12 h before surgery. Anesthesia was
induced and maintained with an isoflurane-air
mixture. Esophagogastroduodenal anastomosis
(EGDA) was performed.
25 In short, a midline
laparotomy was performed, two 1-cm incisions
were made on both the gastroesophageal junction
and on the anti-mesenteric border of the duodenum
and were anastomosed together with accurate
mucosal to mucosal opposition. Care was taken
not to reach the glandular stomach when the
gastroesophageal junction incision was made. Rats
were allowed to drink water at 6 h post-op and
were fed the following day. The Ethics committee
supervising animal studies at the Dongguk
University College of Medicine approved the
experimental design.
Study design
Fifty-one of 60 animals operated on survived
the duration of the experiment. These were divided
into the control group (n = 27), the 500 ppm
sulindac (Sigma, St Louis, MO, USA)-treated
group (n = 15), and the 1000 ppm sulindac-treated
group (n = 9). The sulindac-treated groups (n = 24)
were given rat chow premixed with sulindac. An
additional 12 rats underwent a sham operation
and were given commercial rat chow to obtain
normal esophageal tissue. Each rat was weighed
every week throughout the experiment. Randomly
selected rats were killed by diethyl ether inhalation
on the 20th and 40th weeks after surgery. Rats
were given a single intraperitoneal injection of 0.1
mg/g body weight of bromodeoxyuridine (BrdU)
(Sigma) 1 h before autopsy.
Pathological analysis
The lower esophageal diameters were measured
0.5 cm away from the anastomosis site., Formalin-
fixed tissues were embedded in paraffin, sectioned
at 4 m, and stained with H&E. Lower esophageal μ
inflammation was graded as mild, moderate, or
severe for histological evaluation. Barrett’s
esophagus was diagnosed when mucus-secreting
columnar cells and goblet cells surrounded by
squamous epithelium were present above the
anastomosis site. Adenocarcinoma was diagnosed
when glands with malignant cytological features
were present both at the superficial and deep
portions of the wall.
Immunohistochemistry
Serial 4- m sections were made and spread on μ
poly-L-lysine coated slides. Paraffin sections were
immersed in three changes of xylene and hydrated
using a graded alcohol series. Antigen retrieval
was performed routinely by immersing the
sections in 0.01 M citrate buffer (pH 6.0) and
autoclaving for 15 min. Endogenous peroxidase
activity was blocked with 3% hydrogen peroxide
for 15 min and incubated with monoclonal mouse
anti-BrdU antibody (DakoCytomation, Carpinteria,
CA, USA) overnight in a humidified chamber at
4℃ to localize proliferating cells. Staining was
achieved with a DAKO LSAB + kit (Dako
Cytomation) and developed with diaminobenzidine
tetrahydrochloride (DakoCytomation). Sections
were counterstained for 5 min with Meyer's
hematoxylin and mounted. As a negative control,
mouse IgG isotype (DakoCytomation) was used
instead of primary antibody.
Western blot
Tissue from three rats in the same group was
mixed in a tube and homogenized. Tissues were
suspended in lysis buffer [10 mM Tris-HCl (pH
7.4), 1 mM EDTA, 0.25 M sucrose, 1% Triton X-100]
supplemented with Complete mini proteaseSung Wook Kim, et al.
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inhibitor mixture tablets (Boehringer Mannheim,
Mannheim, Germany) on ice for 1 h. After
removing cell debris by centrifugation, the cell
lysate protein concentration was determined by a
BCA protein assay reagent (Pierce, Rockford, IL,
USA) with a bovine serum albumin standard.
Forty g of protein was separated by 12% SDS- μ
polyacrylamide gel electrophoresis and transferred
to the nitrocellulose membrane. The membranes
were blocked with 5% skim milk in Tris buffered
saline (TBS) for 1 h at room temperature and
probed with antibody overnight at 4℃. The
primary antibodies were polyclonal anti-COX-2
(1:1000, Cayman Chemical, Ann Arbor, MI, USA),
anti- -actin (1 β : 200, Santa Cruz Biotechnology,
Santa Cruz, CA, USA), mouse monoclonal anti-
PCNA (1 : 200, Santa Cruz Biotechnology), and
anti-cyclin D1 (1 : 100, Santa Cruz Biotechnology).
After washing with TBS-0.05% Tween 20, the blots
were treated with horseradish peroxidase-con-
jugated anti-rabbit IgG antibody (1 : 3000; Zymed
Laboratories Inc. San Franciso, CA, USA) or anti-
mouse IgG antibody (1 : 3000. Zymed Laboratories
Inc.) for 1 h at room temperature. Enhanced
chemiluminescence (Pierce) and autoradiography
were used for detection.
Statistical analysis
We used the Kruskal-Wallis test to compare the
lower esophageal diameters among the groups.
When lower esophagus inflammation and Barrett’s
esophagus and adenocarcinoma incidences were
compared, the Fisher’s exact or Chi-square tests
were used. Statistical significance was assumed if
the p value was less than 0.05.
RESULTS
General observation
The respective number of rats examined in the
control and sulindac-treated group were as
follows: 8, 6, and 3 rats at week 20 and 19, 9, and
6 rats at week 40 were in the control, 500 ppm
sulindac group, and 1000 ppm sulindac group,
respectively. A total of 9 rats (4 control and 5
sulindac-treated) died. There was no significant
difference in mortality between the two groups.
Final body weights (g) were 378 ± 21 in the
control, 358 ± 23 in the 500 ppm sulindac, and 392
± 57 in the 1000 ppm sulindac at 20 weeks. They
were 398 ± 40 in the control, 394 ± 48 in the 500
ppm sulindac, and 395 ± 45 in the 1000 ppm
sulindac at 40 weeks. No significant difference in
final body weights was found between the control
and sulindac-treated groups at either time point.
Pathologic findings
The lower esophageal diameters were 10.7 ± 5.2
mm in rats undergoing EGDA and 3.8 ± 0.3 mm in
sham surgery rats. Rat undergoing EGDA showed
an abnormally dilated esophagus compared with
sham surgery rats (p < 0.05). At 20 weeks, the
control rats showed a wider lower esophagus than
sulindac-treated rats, but the difference was not
significant (Fig. 1A) (p > 0.05). At 40 weeks, rats
treated with 1000 ppm sulindac had narrower
esophageal diameters than those of the control
rats (Fig. 1B) (p < 0.05). The lower esophageal
mucosa displayed whitish nodular patches and
superficial ulcers, which were prominent in rats
with a larger lower esophageal diameter. The
stomach and duodenum did not show any
pathologic abnormalities.
At 20 weeks, lower esophageal inflammation
was milder in the rats treated with sulindac than
in the control group, but not significantly so (Fig.
2A) (p > 0.05). At 40 weeks, rats treated with 1000
ppm sulindac showed milder inflammation than
control rats or those treated with 500ppm sulindac
(Fig. 2B) (p < 0.05).
Rats undergoing EGDA showed intestinal
metaplasia including goblet cells above the
esophagoduodenal junction (Fig. 3A) and adeno-
carcinoma characterized by abundant mucin
secretion (Fig. 3B). At 20 weeks, Barrett’s esophagus
incidence was 50% in control rats and the 500
ppm sulindac-treated group and 0% in the 1000
ppm sulindac-treated group. Adenocarcinoma
was present in 37.5% of the control rats and
absent in sulindac-treated rats (Fig. 4A). At 40
weeks, the Barrett’s esophagus incidence was
similar between the control and sulindac-treated
groups, but the incidence of adenocarcinoma was
significantly lower in the 1000 ppm sulindac-Effect of Sulindac on Rat Esophageal Adenocarcinoma
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treated group than the control or 500 ppm
sulindac-treated groups (Fig. 4B) (p < 0.05). BrdU-
labeled columnar cells were located in the upper
and lower portion of Barrett’s esophagus, while in
duodenal mucosa, they were mainly restricted to
the isthmic portion (Figs. 3C and D). Sulindac
treatment did not change this localization (data
not shown).
COX-2, cyclin D1, and PCNA expression
As shown in Fig. 5, COX-2 expression was
significantly increased in rats exposed to gastro-
duodenal reflux contents for 40 weeks compared
with other groups, including the sham surgery
group. Moreover, its expression was localized in
the lower esophagus, which also showed higher
PCNA expression than the stomach and duodenum
(Fig. 6). Cyclin D1 expression was increased in
rats undergoing EGDA compared with those
undergoing the sham surgery and with the
sulindac-treatment groups (Fig. 5).
DISCUSSION
This study shows that sulindac plays a significant
role in preventing the genesis of rat esophageal
adenocarcinoma in surgically induced gastroduo-
denal reflux at least by reducing COX-2 expres-
sion.
A large body of genetic and biochemical evidence
Fig. 1. The lower esophageal diameter of rats undergoing esophagogastroduodenal anastomosis for 20 weeks (A) and 40
weeks (B) according to sulindac treatment. Values are expressed as means ± SD. At 40 weeks, rats treated with 1000 ppm
sulindac showed a diameter narrower than that of the control rats (p < 0.05).
Fig. 2. Lower esophageal inflammation in rats undergoing esophagogastroduodenal anastomosis for 20 weeks (A) and 40
weeks (B) according to sulindac treatment. At 40 weeks, rats treated with 1000 ppm sulindac showed milder inflammation
than control rats or those treated with 500 ppm sulindac (p < 0.05).
A B
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supports a role for COX-2 in human and rodent
tumors.
26,27 The correlation between arachidonic
acid metabolism and tumorigenesis is also sug-
gested by NSAIDs studies. Long-term NSAIDs
and aspirin use protect against esophageal
carcinoma.
21,22 COX-2 expression was increased in
Fig. 3. Histological findings (A, B) and immunohistochemical staining for BrdU (C, D) in the lower esophagus. Rats
undergoing EGDA showed intestinal metaplasia including goblet cells above the esophagoduodenal junction (A) and
adenocarcinoma characterized by abundant mucin secretion (B). BrdU-labeled columnar cells were located in the upper
and lower portions of Barrett’s esophagus (C). In duodenal mucosa, proliferating cells were mainly restricted to the isthmic
portion (D). Magnification, × 200.
Fig. 4. Incidence of Barrett’s esophagus and adenocarcinoma in rats undergoing esophagogastroduodenal anastomosis for
20 weeks (A) and 40 weeks (B) according to sulindac treatment. At 40 weeks, the adenocarcinoma incidence was
significantly lower in rats treated with 1000 ppm sulindac than in the controls or 500 ppm sulindac-treated rats (p = 0.05).
A B
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human esophageal adenocarcinoma.
28,29 Moreover,
a selective COX-2 inhibitor suppressed rat
esophageal adenocarcinoma induced by duodenal
reflux.
23,24,30 In this study, sulindac treatment also
reduced esophageal adenocarcinoma development.
COX-2 expression was also increased in Barrett’s
mucosa in response to acid or bile acid pulses in
an ex vivo organ culture system. This effect was
attenuated by a selective COX-2 inhibitor.
9 The
effect of a COX-2 inhibitor in preventing the
genesis of Barrett’s esophagus in animal studies is
controversial. Buttar et al. did not observe any
suppressive action of COX-2 inhibitors on the
development of Barrett’s esophagus.
24 In contrast,
a recent study reported that a COX-2 inhibitor
prevented the esophageal inflammation-Barrett’s
esophagus-adenocarcinoma sequence in rats.
23 The
present study reveals that the incidence of
Barrett’s esophagus is lower only in rats treated
with 1000 ppm sulindac at 20 weeks. This means
that the genesis of Barrett’s esophagus is
dependent on reflux duration and COX-2 inhibitor
dose.
Increased proliferating cells and an expanded
proliferative compartment were demonstrated in
Barrett’s esophagus and adenocarcinoma.
31,32
Therefore, we studied the localization of BrdU-
labeled cells and cyclin D1 expression. In this
study, BrdU-labeled columnar cells were located
in the upper and lower portions of Barrett’s
esophagus, while they were mainly restricted to
the isthmic portion in duodenal mucosa. This
study showed that cyclin D1 and PCNA expression
were increased in the lower esophagus of rats
exposed to gastroduodenal reflux contents. In
addition, sulindac treatment reduced cyclin D1
expression. Increased nuclear cyclin D1 expression
was observed in 22 - 64% of the esophageal
adenocarcinomas.
33 Recent studies report that
NSAIDs suppress cancer cell growth by inhibiting
cyclin D1 expression.
34,35
In conclusion, we suggest that the chemopre-
ventive effect of sulindac is related to decreased
COX-2 and cyclin D1 expression, which may be
influenced by reduced inflammation.
Fig. 5. Western blot analysis of COX-2 and cyclin D1 expression in the lower esophagus of sham surgery rats and rats
undergoing esophagogastroduodenal anastomosis for 20 weeks and 40 weeks according to sulindac treatment. Forty g μ
of protein was separated by 12% SDS-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane.
Immunoblots were probed with COX-2 and cyclin D1 antibodies. The bottom represents -actin, which was used as a β
loading control.
Fig. 6. Western blot analysis of COX-2 and PCNA expres-
sion in the lower esophagus, stomach, and duodenum of
rats undergoing esophagogastroduodenal anastomosis for
40 weeks. Forty g of protein was separated by 12% μ
SDS-polyacrylamide gel electrophoresis and transferred to
a nitrocellulose membrane. Immunoblots were probed
with COX-2 and PCNA antibodies. The bottom represents
-actin, which was used as a loading control. β
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